Skip to main content

Table 1 Correlations between the four metabolic subtypes and clinical characteristics in the TCGA cohort

From: Identification of subgroups along the glycolysis-cholesterol synthesis axis and the development of an associated prognostic risk model

 

Mixed (n=123)

Cholesterogenic (n=55)

Glycolytic (n=76)

Quiescent (n=90)

Total (n=344)

P value

Age

 Mean (SD)

57.5 (15.4)

54.6 (17.1)

61.1 (14.4)

57.5 (16.5)

57.8 (15.8)

0.159a

 Median [MIN,MAX]

57 [15,90]

56 [19,82]

63 [18,90]

57 [18,90]

58 [15,90]

 

Gender

 Female

44 (35.8%)

18 (32.7%)

29 (38.2%)

38 (42.2%)

129 (37.5%)

0.668b

 Male

79 (64.2%)

37 (67.3%)

47 (61.8%)

52 (57.8%)

215 (62.5%)

 

Race

 Asian

5 (4.1%)

 

2 (2.6%)

2 (2.2%)

9 (2.6%)

 

 White

118 (95.9%)

55 (100.0%)

74 (97.4%)

88 (97.8%)

335 (97.4%)

 

Pathological T

 T0

11 (8.9%)

4 (7.3%)

3 (3.9%)

5 (5.6%)

23 (6.7%)

0.4b

 T1

14 (11.4%)

8 (14.5%)

6 (7.9%)

8 (8.9%)

36 (10.5%)

 

 T2

29 (23.6%)

11 (20.0%)

17 (22.4%)

15 (16.7%)

72 (20.9%)

 

 T3

27 (22.0%)

12 (21.8%)

25 (32.9%)

18 (20.0%)

82 (23.8%)

 

 T4

42 (34.1%)

20 (36.4%)

24 (31.6%)

44 (48.9%)

130 (37.8%)

 

 Tis

  

1 (1.3%)

 

1 (0.3%)

 

Pathological N

 N0

77 (62.6%)

35 (63.6%)

39 (51.3%)

46 (51.1%)

197 (57.3%)

0.693b

 N1

22 (17.9%)

10 (18.2%)

14 (18.4%)

18 (20.0%)

64 (18.6%)

 

 N2

13 (10.6%)

5 (9.1%)

11 (14.5%)

12 (13.3%)

41 (11.9%)

 

 N3

11 (8.9%)

5 (9.1%)

12 (15.8%)

14 (15.6%)

42 (12.2%)

 

Pathological M

     

 M0

122 (99.2%)

51 (92.7%)

72 (94.7%)

87 (96.7%)

332 (96.5%)

0.077b

 M1

1 (0.8%)

4 (7.3%)

4 (5.3%)

3 (3.3%)

12 (3.5%)

 

Pathological stage

     

 Stage I

34 (27.6%)

10 (18.2%)

13 (17.1%)

13 (14.4%)

70 (20.3%)

0.143b

 Stage II

39 (31.7%)

22 (40.0%)

24 (31.6%)

31 (34.4%)

116 (33.7%)

 

 Stage III

49 (39.8%)

18 (32.7%)

35 (46.1%)

41 (45.6%)

143 (41.6%)

 

 Stage IV

1 (0.8%)

4 (7.3%)

4 (5.3%)

3 (3.3%)

12 (3.5%)

 

 I/II NOS

 

1 (1.8%)

 

2 (2.2%)

3 (0.9%)

 

Overall survival

     

 Survival

60 (48.8%)

26 (47.3%)

32 (42.1%)

58 (64.4%)

176 (51.2%)

0.024c (*)

 Death

63 (51.2%)

29 (52.7%)

44 (57.9%)

32 (35.6%)

168 (48.8%)

 

Progress-free interval

     

 Free survival

37 (30.1%)

11 (20.0%)

16 (21.1%)

43 (47.8%)

107 (31.1%)

<0.001c (*)

 Death or progression

86 (69.9%)

44 (80.0%)

60 (78.9%)

47 (52.2%)

237 (68.9%)

 
  1. T, tumor; N, lymph node; M, metastasis; P values were calculated by the Kruskal testa, chi-square testb, or log-rank testc; *statistically significant